254 related articles for article (PubMed ID: 19148578)
1. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
Muñoz M; Rosso M
Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
[TBL] [Abstract][Full Text] [Related]
2. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
[TBL] [Abstract][Full Text] [Related]
3. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract][Full Text] [Related]
4. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M
Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096
[TBL] [Abstract][Full Text] [Related]
5. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.
Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F
Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845
[TBL] [Abstract][Full Text] [Related]
6. The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile.
Muñoz M; Rosso M; González A; Saenz J; Coveñas R
Peptides; 2010 Sep; 31(9):1643-8. PubMed ID: 20542069
[TBL] [Abstract][Full Text] [Related]
7. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
8. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
9. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
10. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
11. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
12. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Robinson P; Coveñas R; Muñoz M
Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
[TBL] [Abstract][Full Text] [Related]
14. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.
Muñoz M; Rosso M; Coveñas R; Montero I; González-Moles MA; Robles MJ
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2775-81. PubMed ID: 17525212
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
17. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
[TBL] [Abstract][Full Text] [Related]
18. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
20. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
